Steven has made over 32 trades of the Caladrius Biosciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 347,206 units of CLBS stock worth $20,832,360 on 4 December 2019.
The largest trade he's ever made was selling 347,206 units of Caladrius Biosciences Inc stock on 4 December 2019 worth over $20,832,360. On average, Steven trades about 15,334 units every 27 days since 2003. As of 23 October 2018 he still owns at least 103,328 units of Caladrius Biosciences Inc stock.
You can see the complete history of Mr. Klosk stock trades at the bottom of the page.
Steven Mark Klosk serves as Independent Director of the Company. He is a senior executive with extensive management experience in the life sciences industry. He is currently CEO and a Director at Cambrex Corporation (NYSE:CBM), one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets. Mr. Klosk has been in his current role since May 2008 and is responsible for all aspects of Cambrex’s global business with manufacturing and R&D facilities in the United States, Sweden, Italy, Estonia and Germany. Mr. Klosk held other executive positions at Cambrex Corporation, including President, Executive Vice President & COO; as well as President, Pharma Business Unit (2007-2008) where he had full P&L and balance sheet responsibility for four operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Business Unit (2003-2007) where he was responsible for managing a highly profitable global business with six operating units in North America and Europe. Earlier in his career Mr. Klosk served as Vice President, Administration for The Genlyte Group, Inc., a publicly traded producer of lighting fixtures. Mr. Klosk earned a B.S. from Cornell University and a J.D. from New York Law School.
Steven Klosk is 63, he's been the Independent Director of Caladrius Biosciences Inc since 2014. There are 5 older and 9 younger executives at Caladrius Biosciences Inc. The oldest executive at Caladrius Biosciences Inc is Steven Myers, 73, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O CALADRIUS BIOSCIENCES, INC., 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE, NJ, 07920.
Over the last 9 years, insiders at Caladrius Biosciences Inc have traded over $244,786 worth of Caladrius Biosciences Inc stock and bought 202,695 units worth $275,173 . The most active insiders traders include Richard J Berman, Steven M Klosk, and Peter G Traber. On average, Caladrius Biosciences Inc executives and independent directors trade stock every 178 days with the average trade being worth of $17,064. The most recent stock trade was executed by Steven S Myers on 8 December 2021, trading 33,785 units of CLBS stock currently worth $30,069.
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
Caladrius Biosciences Inc executives and other stock owners filed with the SEC include: